These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33915115)

  • 1. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
    Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
    Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of conservative surgery for pancreatic IPMNs.
    Palmeri M; Di Franco G; Bianchini M; Guadagni S; Gianardi D; Furbetta N; Caprili G; Fatucchi LM; Sbrana A; Funel N; Pollina LE; Di Candio G; Morelli L
    Surg Oncol; 2021 Sep; 38():101582. PubMed ID: 33892432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
    Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
    Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
    Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Kimura K; Amano R; Ymazoe S; Ohira G; Nishio K; Hirakawa K; Ohira M
    World J Surg; 2017 May; 41(5):1358-1365. PubMed ID: 27882420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium.
    Attiyeh MA; Fernández-Del Castillo C; Al Efishat M; Eaton AA; Gönen M; Batts R; Pergolini I; Rezaee N; Lillemoe KD; Ferrone CR; Mino-Kenudson M; Weiss MJ; Cameron JL; Hruban RH; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Wolfgang CL; Allen PJ
    Ann Surg; 2018 Jan; 267(1):157-163. PubMed ID: 28079542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
    Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
    HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Yamaue H
    Surg Today; 2020 Jan; 50(1):50-55. PubMed ID: 31807871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade dysplasia and adenocarcinoma are frequent in side-branch intraductal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound.
    Wong J; Weber J; Centeno BA; Vignesh S; Harris CL; Klapman JB; Hodul P
    J Gastrointest Surg; 2013 Jan; 17(1):78-84; discussion p.84-5. PubMed ID: 22948841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery.
    Marchegiani G; Pollini T; Andrianello S; Tomasoni G; Biancotto M; Javed AA; Kinny-Köster B; Amini N; Han Y; Kim H; Kwon W; Kim M; Perri G; He J; Bassi C; Goh BK; Katz MH; Jang JY; Wolfgang C; Salvia R
    JAMA Surg; 2021 Jul; 156(7):654-661. PubMed ID: 34009303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis.
    Winter JM; Jiang W; Basturk O; Mino-Kenudson M; Fong ZV; Tan WP; Lavu H; Vollmer CM; Furth EE; Haviland D; Klimstra DS; Jarnagin WR; Lillemoe KD; Yeo CJ; Fernandez-Del Castillo C; Allen PJ
    Ann Surg; 2016 Apr; 263(4):793-801. PubMed ID: 26135696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
    Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
    Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center.
    Cui M; Hu Y; Zheng B; Chen T; Dai M; Guo J; Zhang T; Yu J; Liao Q; Zhao Y
    Dig Surg; 2024; 41(3):111-121. PubMed ID: 38981458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
    Takahashi H; Nakamori S; Nakahira S; Tsujie M; Takahshi Y; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Ann Surg Oncol; 2006 Jul; 13(7):955-60. PubMed ID: 16788757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.